Biglycan stimulates VEGF expression in endothelial cells by activating the TLR signaling pathway

Molecular Oncology

Volumn 10, Issue 9, 2016, Pages 1473-1484

  Hu, Lei ^a   Zang, Ming de ^a   Wang, He xiao ^a   Li, Jian fang ^a   Su, Li ping ^a   Yan, Min ^a   Li, Chen ^a   Yang, Qiu meng ^a   Liu, Bing ya ^a   Zhu, Zheng gang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Angiogenesis; BGN; Endothelial cells; GC; TLR2 4; VEGF

Indexed keywords

BIGLYCAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; RECOMBINANT PROTEIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; VASCULOTROPIN; PROTEIN BINDING; TOLL LIKE RECEPTOR; VASCULOTROPIN A;

ARTICLE; BINDING SITE; CANCER CELL; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; STOMACH CANCER; ANGIOGENESIS; BIOLOGICAL MODEL; CELL MOTION; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; STOMACH TUMOR; UMBILICAL VEIN ENDOTHELIAL CELL;

BIGLYCAN; CELL MOVEMENT; CELL PROLIFERATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PHYSIOLOGIC; NF-KAPPA B; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TOLL-LIKE RECEPTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84994078751     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2016.08.002     Document Type: Article

References (40)

1. Biddle, A., Mackenzie, I.C., Cancer stem cells and EMT in carcinoma. Cancer Metastasis Rev. 31 (2012), 285–293.
2. Boehmer, E.D., Meehan, M.J., Cutro, B.T., et al. Aging negatively skews macrophage TLR2- and TLR4-mediated pro-inflammatory responses without affecting the IL-2-stimulated pathway. Mech. Ageing Dev. 126 (2005), 1305–1313.
3. Dolcet, X., Llobet, D., Pallares, J., et al. NF-kB in development and progression of human cancer. Virchows Arch. 446 (2005), 475–482.
4. Ellenrieder, V., Hendler, S.F., Boeck, W., et al. Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res. 61 (2001), 4222–4228.
5. Horemans, T., Boulet, G., van Kerckhoven, M., et al. In-vivo evaluation of apocynin for prevention of Helicobacter pylori-induced gastric carcinogenesis. Eur. J. Cancer Prev., 2016 [Epub ahead of print].
6. Hsieh, L.T., Nastase, M.V., Zeng-Brouwers, J., et al. Soluble biglycan as a biomarker of inflammatory renal diseases. Int. J. Biochem. Cell Biol. 54 (2014), 223–235.
7. Hu, L., Duan, Y.T., Li, J.F., et al. Biglycan enhances gastric cancer invasion by activating FAK signaling pathway. Oncotarget 5 (2014), 1885–1896.
8. Imtiyaz, H.Z., Simon, M.C., Hypoxia-inducible factors as essential regulators of inflammation. Curr. Top. Microbiol. Immunol. 345 (2010), 105–120.
9. Johnson, A.C., Heinzel, F.P., Diaconu, E., et al. Activation of toll-like receptor (TLR)2, TLR4, and TLR9 in the mammalian cornea induces MyD88-dependent corneal inflammation. Invest. Ophthalmol. Vis. Sci. 46 (2005), 589–595.
10. Kakeji, Y., Koga, T., Sumiyoshi, Y., et al. Clinical significance of vascular endothelial growth factor expression in gastric cancer. J. Exp. Clin. Cancer Res. 21 (2002), 125–129.
11. Karin, M., Nuclear factor-kappaB in cancer development and progression. Nature 441 (2006), 431–436.
12. Kazemi, E., Kahrizi, D., Moradi, M.T., et al. Gastric cancer and helicobacter pylori: impact of hopQII gene. Cell. Mol. Biol. (Noisy-le-grand) 62 (2016), 107–110.
13. Liang, X., Zeng, J., Wang, L., et al. Histone demethylase RBP2 induced by helicobactor pylori CagA participates in the malignant transformation of gastric epithelial cells. Oncotarget 5 (2014), 5798–5807.
14. Mantovani, A., Allavena, P., Sica, A., et al. Cancer-related inflammation. Nature 454 (2008), 436–444.
15. Martinez, E.F., Araujo, V.C., In vitro immunoexpression of extracellular matrix proteins in dental pulpal and gingival human fibroblasts. Int. Endod. J. 37 (2004), 749–755.
16. Mikula, M., Rubel, T., Karczmarski, J., et al. Integrating proteomic and transcriptomic high-throughput surveys for search of new biomarkers of colon tumors. Funct. Integr. Genomics 11 (2010), 215–224.
17. Moon, W.S., Rhyu, K.H., Kang, M.J., et al. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma?. Mod. Pathol. 16 (2003), 552–557.
18. Moreth, K., Frey, H., Hubo, M., et al. Biglycan-triggered TLR-2- and TLR-4-signaling exacerbates the pathophysiology of ischemic acute kidney injury. Matrix Biol. 35 (2014), 143–151.
19. Piazuelo, M.B., Correa, P., Gastric cancer: overview. Colomb. Med. (Cali) 44 (2013), 192–201.
20. Pugh, C.W., Ratcliffe, P.J., Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 9 (2003), 677–684.
21. Riddell, J.R., Maier, P., Sass, S.N., et al. Peroxiredoxin 1 stimulates endothelial cell expression of VEGF via TLR4 dependent activation of HIF-1alpha. PLoS One, 7, 2012, e50394.
22. Salven, P., Ruotsalainen, T., Mattson, K., et al. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int. J. Cancer 79 (1998), 144–146.
23. Schaefer, L., Babelova, A., Kiss, E., et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J. Clin. Invest. 115 (2005), 2223–2233.
24. Shi, Y.H., Wang, Y.X., Bingle, L., et al. In vitro study of HIF-1 activation and VEGF release by bFGF in the T47D breast cancer cell line under normoxic conditions: involvement of PI-3K/Akt and MEK1/ERK pathways. J. Pathol. 205 (2005), 530–536.
25. Skobe, M., Hawighorst, T., Jackson, D.G., et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 7 (2001), 192–198.
26. Sommer, B., Bickel, M., Hofstetter, W., et al. Expression of matrix proteins during the development of mineralized tissues. Bone 19 (1996), 371–380.
27. Tlsty, T.D., Coussens, L.M., Tumor stroma and regulation of cancer development. Annu. Rev. Pathol. 1 (2006), 119–150.
28. Tokunaga, T., Oshika, Y., Abe, Y., et al. Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br. J. Cancer 77 (1998), 998–1002.
29. Weber, C.K., Sommer, G., Michl, P., et al. Biglycan is overexpressed in pancreatic cancer and induces G1-arrest in pancreatic cancer cell lines. Gastroenterology 121 (2001), 657–667.
30. Wu, C.Y., Wang, C.J., Tseng, C.C., et al. Helicobacter pylori promote gastric cancer cells invasion through a NF-kappaB and COX-2-mediated pathway. World J. Gastroenterol. 11 (2005), 3197–3203.
31. Xiao, C., Ghosh, S., NF-kappaB, an evolutionarily conserved mediator of immune and inflammatory responses. Adv. Exp. Med. Biol. 560 (2005), 41–45.
32. Xing, X., Gu, X., Ma, T., et al. Biglycan up-regulated vascular endothelial growth factor (VEGF) expression and promoted angiogenesis in colon cancer. Tumour Biol. 36 (2015), 1773–1780.
33. Yamamoto, K., Ohga, N., Hida, Y., et al. Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells. Br. J. Cancer 106 (2012), 1214–1223.
34. Yonemura, Y., Endo, Y., Fujita, H., et al. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin. Cancer Res. 5 (1999), 1823–1829.
35. Zeng-Brouwers, J., Beckmann, J., Nastase, M.V., et al. De novo expression of circulating biglycan evokes an innate inflammatory tissue response via MyD88/TRIF pathways. Matrix Biol. 35 (2014), 132–142.
36. Zhang, B.G., Hu, L., Zang, M.D., et al. Helicobacter pylori CagA induces tumor suppressor gene hypermethylation by upregulating DNMT1 via AKT-NFkappaB pathway in gastric cancer development. Oncotarget 7 (2016), 9788–9800.
37. Zhao, M., Lu, Y., Takata, T., et al. Immunohistochemical and histochemical characterization of the mucosubstances of odontogenic myxoma: histogenesis and differential diagnosis. Pathol. Res. Pract. 195 (1999), 391–397.
38. Zheng, H., Takahashi, H., Murai, Y., et al. Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res. 26 (2006), 3579–3583.
39. Zhu, Y.H., Yang, F., Zhang, S.S., et al. High expression of biglycan is associated with poor prognosis in patients with esophageal squamous cell carcinoma. Int. J. Clin. Exp. Pathol. 6 (2013), 2497–2505.
40. Zigrino, P., Loffek, S., Mauch, C., Tumor-stroma interactions: their role in the control of tumor cell invasion. Biochimie 87 (2005), 321–328.